Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. - Wikidata - awgldk - TriplyDB

Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer.

Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer.

http://www.wikidata.org/entity/Q45770152

about

Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer.Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer Lung cancer: Biology and treatment options.Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3 The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy.Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.Treating ALK-positive lung cancer--early successes and future challenges.Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer.Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer.Worse disease-free, tumor-specific, and overall survival in surgically-resected lung adenocarcinoma patients with ALK rearrangement.ALK protein expression in pulmonary adenocarcinoma of Tunisian patients.[Clinical Advanced in Early-stage ALK-positive Non-small Cell Lung Cancer Patients].

P2860

Q34564071-11006512-7357-48D9-9EF8-9E87118F1BAE Q34566472-B554AFB8-6B9B-43F0-9431-989C0984BA66 Q34886787-3AC9E7A0-6A98-4869-8F82-FE1542D86448 Q35429767-056B0C09-C93E-4548-9A6A-E781C4236889 Q36260477-E4932165-FA02-4A23-BAAF-AA7C2C324BF0 Q36328370-42A0E2A8-7C70-4E60-8D19-3D9A8A889CB0 Q36405628-11041119-8D62-4166-ADF2-53F896600479 Q36474900-B4582DB7-6663-474B-AB4B-46406062CA22 Q36821217-717C4015-9149-47EC-BFBB-318CCCE726AE Q37431563-DE97B101-C82C-4226-A79C-9B5C1E3B9A30 Q37606591-11B21E9A-4FCB-4A55-91FB-563811A3DF0A Q37999657-8AAA6791-E98C-4E39-9983-A5D255B8A887 Q38148969-CA8E545F-E3E6-4678-9243-BCC0C65A6DF2 Q38214154-2A4C355A-EC28-48F7-B6F3-C914B4776DB1 Q38219688-7C6BD425-BB7B-4614-A1B8-AEC7032EEE19 Q38241120-9423B433-42E2-4B9C-91AA-29973C962ECD Q38739807-5E7BB334-611A-4F0C-A31F-EAC1296D3728 Q47097774-E7FCB935-3BC8-443C-9FCD-F1D1980FD23F Q51049573-54D940FA-D016-4757-9584-54CEF480E285 Q52902964-4177ABC0-57D9-430F-875A-6D5E842FF0EC

P2860

Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer.

http://www.wikidata.org/entity/Q45770152

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Comparative analyses of overal ...... ced nonsmall cell lung cancer.

@en

Comparative analyses of overal ...... ced nonsmall cell lung cancer.

@nl

type

label

Comparative analyses of overal ...... ced nonsmall cell lung cancer.

@en

Comparative analyses of overal ...... ced nonsmall cell lung cancer.

@nl

prefLabel

Comparative analyses of overal ...... ced nonsmall cell lung cancer.

@en

Comparative analyses of overal ...... ced nonsmall cell lung cancer.

@nl

P1433

Q45770152-9C0A3DF5-52C1-4162-9CD2-967A745E9AE8

P1476

Q45770152-985D5AD5-C755-4FD3-B5DE-5C3C440B2516

P2093

Q45770152-195C3A8C-7DE5-4E84-BA5F-7230923B3982

Q45770152-1B6B9071-892C-4E45-B707-452749953B5F

Q45770152-3CCD537C-476E-4910-8834-C300FA9FE9FC

Q45770152-6132AD40-0A36-40D4-9A59-80284CB29339

Q45770152-64D29298-4D4D-4094-A359-02DBBC0B1DB0

Q45770152-875A016F-0D91-442A-B831-F1B0238B4BB3

Q45770152-99FBD3CB-19FA-4100-AFAE-5B031254913B

Q45770152-AD0B0226-2884-473D-BB1E-93E5423D926B

Q45770152-B2188044-18B1-4787-81B1-083E091CC49C

Q45770152-ED8C8121-03BB-4447-BC4B-C5891C2F9815

P2860

Q45770152-0BC5E77E-E0EB-450B-8FDC-4E2B0265D09E

Q45770152-1459F5E0-7204-43D3-8C96-FED81266EFB1

Q45770152-245E6117-35C1-4A33-8B0A-E6CB7BC565A8

Q45770152-24855337-3AB1-41AC-8993-C7C81F3B9FA4

Q45770152-27BDDF4F-C52E-4AD6-B8BA-679F83F4B356

Q45770152-293BEB98-D5E2-4C7B-BC4C-03D7216E628F

Q45770152-29FCE2F4-28EF-4156-BDB8-774BE330E9F9

Q45770152-36B1AB60-F94B-4992-BE9E-24B380050500

Q45770152-4F329826-B232-4012-B943-6852C87E91D0

Q45770152-52CDAF53-E47C-4A13-A082-C2F0F76ABBE8

P304

Q45770152-37A8802C-E725-49C3-AC95-A12F4953EFA1

P31

Q45770152-84211E18-57E8-4119-9DF1-23A6B9F7358C

P356

Q45770152-BCEFD7D3-07D7-4C28-8C57-DF9B57AEFE5C

P407

Q45770152-73A44318-2409-4FD4-B922-2AB30C8A7318

P433

Q45770152-968E1EFA-40EA-4838-B993-933D59F08D23

P478

Q45770152-1EAF13F2-5C15-42A5-AFD8-94ED29004F47

P577

Q45770152-76455486-83B7-4C66-BE46-BFCD5187618E

P5875

Q45770152-2DF59004-BDE3-4C7E-A18C-08A4278BA3AF

P698

Q45770152-74E8402F-2A5B-4721-AB5D-2767F9ADAC64

P356

P1433

P1476

Comparative analyses of overal ...... ced nonsmall cell lung cancer.

@en

P2093

Dae Seog Heo

http://www.w3.org/2001/XMLSchema#string

Dong-Wan Kim

http://www.w3.org/2001/XMLSchema#string

Doo Hyun Chung

http://www.w3.org/2001/XMLSchema#string

Heae Surng Park

http://www.w3.org/2001/XMLSchema#string

June Koo Lee

http://www.w3.org/2001/XMLSchema#string

Kimary Kulig

http://www.w3.org/2001/XMLSchema#string

Se-Hoon Lee

http://www.w3.org/2001/XMLSchema#string

Tae Min Kim

http://www.w3.org/2001/XMLSchema#string

Woo-Ho Kim

http://www.w3.org/2001/XMLSchema#string

Yoon-Kyung Jeon

http://www.w3.org/2001/XMLSchema#string

P2860

The biology and treatment of EML4-ALK non-small cell lung cancer

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Cancer. Addiction to oncogenes--the Achilles heal of cancer

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

P304

3579-3586

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.26668

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51801846

http://www.w3.org/2001/XMLSchema#string

P698

22086654

http://www.w3.org/2001/XMLSchema#string